title: Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer.
abstract: OBJECTIVE
  To evaluate the prognostic value of immunohistochemical expression of Bcl-2 in colon cancers.
  
  
  METHODS
  Two hundred and twenty-six resected and paraffin-embedded colon carcinomas were analysed by immunostaining using monoclonal antibodies for Bcl-2. We evaluated whether the Bcl-2 staining patterns, semi-quantitatively assessed, could be correlated with the pTNM stage, size and tumour circumference, differentiation, appearance, vascular invasion, perineural invasion, colloid component, margins, involvement of adjacent structures, stromal appearance, flow cytometry and the S-phase.
  
  
  RESULTS
  Eighty patients (36%) were considered Bcl-2 positive. The extent of Bcl-2 expression by tumour cells decreased significantly with respect to increasing tumour size (P=0.042), the extension of parietal invasion pT (P=0.007), the invasive nature of the tumour (P=0.024), and extent of the circumference (P=0.024). In a multivariate analysis, Bcl-2 expression does not appear as an independent prognosis factor in the overall population as in the 166 patients with optimal resection. Of the 59 stage II patients, using univariate analysis, Bcl-2 appears to be predictive of relapse-free survival (P=0.025) but not of overall survival (P=0.09).
  
  
  CONCLUSIONS
  The loss of Bcl-2 expression appears to be correlated with increase in number of relapses in the stage II colon cancers and could be a potential useful additional histo-prognostic marker in therapy decision making. Bcl-2 immunodetection seems to be associated with slower local tumour growth.
authors.affiliation: Department of Gastroenterology CHRU, Hotel-Dieu, 63000 Clermont-Ferrand, France. lpoincloux@chu-clermontferrand.fr
authors.forename: Laurent
authors.initials: L
authors.lastname: Poincloux
authors.forename: Xavier
authors.initials: X
authors.lastname: Durando
authors.forename: Jean François
authors.initials: JF
authors.lastname: Seitz
authors.forename: Emilie
authors.initials: E
authors.lastname: Thivat
authors.forename: Valérie-Jeanne
authors.initials: VJ
authors.lastname: Bardou
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Giovannini
authors.forename: Danièle
authors.initials: D
authors.lastname: Parriaux
authors.forename: Nicolas
authors.initials: N
authors.lastname: Barriere
authors.forename: Marc
authors.initials: M
authors.lastname: Giovannini
authors.forename: Jean-Robert
authors.initials: JR
authors.lastname: Delpero
authors.forename: Geneviève
authors.initials: G
authors.lastname: Monges
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism*; D002277:Carcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D002455:Cell Division / Q000235:genetics; D003110:Colonic Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000378:metabolism; D009367:Neoplasm Staging; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D019253:Proto-Oncogene Proteins c-bcl-2